21h
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...
Chinese biotech Laekna Therapeutics on Wednesday announced a clinical collaboration with Eli Lilly (NYSE:LLY) to develop an ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
On November 20, Gabrielle Sulzberger, Director at Eli Lilly LLY executed a significant insider buy, as disclosed in the latest SEC filing. What Happened: In a significant move reported in a Form 4 ...
Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.
Conditions are getting a bit more challenging for the drugmaker.
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $1,000.00. Don't Miss our Black Friday Offers: Mohit Bansal ...
The stock has also performed well this year, rising roughly 36% (as of Nov. 14), ahead of the broader market. Given that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback